Inhibikase Therapeutics Files 2024 10-K
Ticker: IKT · Form: 10-K · Filed: Mar 27, 2025 · CIK: 1750149
Sentiment: neutral
Topics: 10-K, biotech, financials
TL;DR
IKT 2024 10-K filed. Financials and operations for FY24 detailed. Check warrants & 2020 Plan updates.
AI Summary
Inhibikase Therapeutics, Inc. filed its 2024 10-K on March 27, 2025, reporting on its fiscal year ending December 31, 2024. The company, focused on biological products, is based in Atlanta, GA. Key dates mentioned include September 30, 2024, and October 21, 2024, related to warrants, and a subsequent event on January 3, 2025, concerning the 2020 Plan.
Why It Matters
This filing provides a comprehensive overview of Inhibikase Therapeutics' financial health and operational status for the fiscal year 2024, crucial for investors assessing the company's performance and future prospects.
Risk Assessment
Risk Level: medium — The company operates in the biotechnology sector, which is inherently high-risk due to research and development uncertainties and regulatory hurdles.
Key Players & Entities
- Inhibikase Therapeutics, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-27 (date) — Filing date
- Atlanta, GA (location) — Company business address
- 2024-09-30 (date) — Warrant related date
- 2024-10-21 (date) — Warrant related date
- 2025-01-03 (date) — Subsequent event date
FAQ
What is the primary business of Inhibikase Therapeutics, Inc.?
Inhibikase Therapeutics, Inc. is primarily involved in Biological Products (No Diagnostic Substances), as indicated by its SIC code [2836].
When did Inhibikase Therapeutics, Inc. file its 10-K report?
The 10-K report was filed on March 27, 2025.
What fiscal year does this 10-K filing cover?
This 10-K filing covers the fiscal year ending December 31, 2024.
What is the company's business address?
The company's business address is 3350 Riverwood Parkway SE, Suite 1900, Atlanta, GA 30339.
Are there any significant subsequent events mentioned in the filing?
Yes, a subsequent event related to the 'TwoThousandAndTwentyPlanMember' occurred on January 3, 2025.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 27, 2025 regarding Inhibikase Therapeutics, Inc. (IKT).